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T
he development of cutaneous pathological 
scars, namely, hypertrophic scars (HSs) and ke-
loids, involves complex pathways, and the exact 
mechanisms by which they are initiated, evolved, and 
are regulated remain to be fully elucidated. The ef-
forts to understand the pathogenesis of these scars 
are complicated further by the fact that the clini-
cal diagnosis does not always correlate with the his-
tological diagnosis. This is because there is conflict 
regarding the precise histopathological criteria that 
distinguish keloids from HS, which arises from the 
fact that the pathological manifestations of these le-
sions overlap.1 Thus, the generally held concepts that 
keloids and HSs represent “aberrant wound healing” 
or that they are “characterized by hyalinized collagen 
bundles” have done little to promote their accurate 
clinicopathological classification or to stimulate re-
search into the specific causes of these scars and ef-
fective interventions.
To overcome this barrier, it is necessary to elucidate 
the relevant clinical and histopathological manifesta-
tions of these important lesions and to   understand 
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“aberrant wound healing” or that they are “characterized by hyalinized colla-
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classification or to stimulate research into the specific causes of these scars 
and effective preventative therapies. To overcome this barrier, we review 
here the most recent findings regarding the pathology and pathogenesis of 
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how these manifestations relate to each other. In this 
article, we review the most recent findings regarding 
the pathology and pathogenesis of keloids and HSs. 
In particular, the significant roles of the extracellular 
matrix (ECM) and the epidermal and dermal layers 
of skin in scar pathogenesis are examined. The ab-
errations of HSs and keloids in terms of the inflam-
mation, proliferation, and remodeling phases of the 
wound healing process are also described. Finally, the 
current hypotheses of pathological scar etiology that 
should be tested by basic and clinical investigators 
are detailed. Effective therapies, including several 
that evolved directly from the aforementioned etiol-
ogy hypotheses, are also described.
PHASES IN PATHOLOGICAL SCAR 
FORMATION
Pathological scars are generally accepted to be 
the result of prolonged, aberrant wound healing 
that involves excessive fibroblast participation and 
collagen deposition. In normal wound healing, 
wounding is rapidly followed by an initial inflamma-
tory phase where the fibrin clot releases chemotac-
tic factors that initiate leukocyte migration into the 
wounded area. Neutrophils are among the earliest 
cells to infiltrate. They are eventually replaced with 
macrophages; this event marks the end of the early 
inflammatory phase and the beginning of the late 
inflammatory phase.2 The proliferation phase then 
follows. In abnormal wound healing, abundant mac-
rophages inappropriately release cytokines during 
the transition between the late inflammatory and 
proliferation phases. This prolongs inflammation 
and delays the healing response. This is a key event 
that drives the formation of keloids and HSs.1,3 No-
tably, wounds devoid of neutrophils heal normally,4 
which suggests that neutrophils are not necessary for 
the participation of macrophages in normal wound 
healing. The proliferation phase is followed by the 
remodeling phase. Here, new ECM molecules are 
deposited in an orderly sequence: fibronectin, fol-
lowed by collagen type III, and then collagen type I.5 
Because of this collagen remodeling, the strength of 
the scar tissue increases gradually, and it reaches a 
plateau about 7 weeks after wounding. The resulting 
maximum scar tissue tensile strength is 70% that of 
normal skin (Fig. 1).6,7
CELLULAR AND EXTRACELLULAR 
ALTERATIONS IN EPIDERMAL AND 
DERMAL LAYERS
The typical pathognomonic characteristics of ke-
loids are the presence of thickened and hyalinized 
(“keloidal”) collagen.8 By contrast, HSs are con-
trasted by the expression of α-smooth muscle actin 
(α-SMA) and whorl-like or nodular arrangements of 
collagen fibers.9 These features of HSs and keloids 
are associated with important changes in cells and 
the ECM in the epidermal and dermal layers.
The Epidermal Layer
The primary event in the formation of HSs and 
keloids is traditionally regarded to be fibrosis in the 
dermal layer. However, recent work suggests that 
the epidermis and its cross talk with the underly-
ing dermis play a significant role in cutaneous scar 
pathology. The epidermis of HSs overexpresses 
  cyclooxygenase-1 compared to the epidermis of 
normal skin and keloid specimens, whereas the epi-
dermis of keloids overexpresses cyclooxygenase-2 
compared to the epidermis of normal skin and HS 
samples. These findings underline the importance 
of   epithelial–mesenchymal interactions in cutane-
ous scar pathogenesis.10
Growing evidence shows that epidermal Lang-
erhans cells (LCs) and keratinocytes participate ac-
tively in scar pathogenesis. Relative to normal scars, 
HSs have increased numbers of epidermal LCs, in-
creased epidermal interleukin-4 expression, and re-
duced epidermal interleukin-1α expression, which 
indicates that the epidermal regulation of dermal 
remodeling is aberrant in HS formation.11,12 By con-
trast, in keloids, the intraepidermal LC numbers do 
not differ significantly from those in normal scars 
or normal skins but increased infiltration of cells 
such as T cells, B cells, and alternative macrophages 
(M2) is observed. This supports the notion that 
  keloids may be driven in part by T cell–keratinocyte– 
fibroblast interactions.13 Epidermal keratinocytes 
intercommunicate with underlying fibroblasts, and 
this intercommunication plays an important role in 
HS and keloid formation. In keloids, keratinocytes 
induce fibroblasts to secrete connective tissue growth 
factor in a paracrine fashion.14 Connective tissue 
growth factor is a cofactor or a downstream mediator 
of the role of transforming growth factor β in enhanc-
ing fibrosis. Keratinocytes also directly increase the 
proliferation of underlying dermal fibroblasts while 
decreasing their collagen production.15 In HS, the 
keratinocytes are activated, with enhanced expres-
sion of keratins K6 and K16. This activation may delay 
reepithelialization, prolong epidermal inflamma-
tion, and invoke abnormal epidermal–mesenchymal   
interactions.16 These observations suggest that 
wounds such as severe thermal injuries may tend to 
become hypertrophic because the collagen produc-
tion of the fibroblasts is not adequately regulated by 
keratinocytes and their products; this ultimately re-
sults in excessive collagen production.  Huang et al. • Keloid and Hypertrophic Scar Pathology
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The Dermal Layer
Dermal Constituents: Collagen, Hyaluronan, and  
Fibronectin
Collagen forms most of the 2 dermal layers (pap-
illary and reticular dermis) and is the main compo-
nent in both HSs and keloids. In HSs, the collagen 
fibers that run parallel to the epithelial surface in 
normal skin are replaced by an expanded dermis 
that is composed of flatter and less clearly demar-
cated, loosely arrayed wavy collagen bundles that are 
somewhat fragmented and shortened (although the 
majority of the bundles still run parallel to the epi-
thelial surface).17 In keloids, the dermis is even more 
expanded. The collagen bundles and the fibers, 
which are composed of numerous fibrils that are 
closely packed together, are thicker and have larger 
bundle distances (the average distance between the 
centers of the collagen bundles) than those in nor-
mal skin, normotrophic scars, and HSs.18 Moreover, 
the large, hyalinized, and strongly eosinophilic colla-
gen (keloidal) fibers are randomly oriented in swirls 
and whorls and vary in their length.17,19 This thick-
ened, hyalinized collagen is used for differential 
diagnosis even though it is only detected in 55% of 
keloid specimens.8 Keloid scars that lack detectable 
hyalinized collagen can be diagnosed instead on the 
basis of other characteristic features, namely, a non-
flattened epidermis, a non-fibrotic papillary dermis, 
a tongue-like advancing edge, horizontal cellular fi-
brous bands in the upper reticular dermis, and the 
presence of prominent fascia-like bands.8
Differential diagnosis can also be made on the ba-
sis of the collagen fiber composition: in keloids, type I 
procollagen levels are increased (compared to normal 
skin), and this is paralleled with an increase in its mes-
senger RNA (mRNA) levels. However, type III procol-
lagen mRNA levels are unaltered. Thus, the type I/III 
procollagen mRNA ratio in keloids is markedly elevat-
ed (22.1) relative to the ratio in normal skin (5.2).20 By 
contrast, as shown by another study, in HS, the type I/
III collagen ratio is on average 7.73; this is significantly 
lower than the ratio of keloids (17.28) and similar to 
the ratio of normal skin (6.28). The pretranscription-
al regulation of collagen I production is impaired in 
both scar types, whereas the posttranscriptional regu-
lation is impaired in keloids only.21
Notably, keloid cell cultures also show lower 
degradation of newly synthesized collagen polypep-
tides than normal controls, which suggests that the 
accumulation of collagen may also be due to the 
reduced degradation of these polypeptides.22 Simi-
larly, there is a significant reduction in collagenase 
mRNA and activity in HS fibroblasts; this supports 
the possibility that these factors contribute to the 
Fig. 1. Wound healing in pathological scars is characterized by a prolonged and stronger inflammation phase with inappro-
priately released cytokines followed by a subsequent delay in the healing response. bFGF, basic fibroblast growth factor; eGF, 
epithelial growth factor; NGF, nerve growth factor; TGFβ, transforming growth factor β; TNFα, tumor necrosis factor α; VeGF, 
vascular endothelial growth factor.PRS GO • 2013
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excessive deposition of collagen in these aberrant 
scars.23
Unlike normal skin, both keloids and HSs have 
dermal nodules that are composed of focal aggre-
gates of fibroblasts and randomly oriented collagen 
fibers. One study showed that the borders of these 
dermal nodules are well demarcated in HSs but less 
distinct in keloids.24 Another study suggested that 
dermal nodules are a histological characteristic of 
HSs that are absent in keloids.9
Hyaluronan and fibronectin are also indispens-
able dermal ECM ingredients in pathological scars. 
In HSs, hyaluronan is mainly found as a narrow 
strip in the papillary dermis, whereas in keloids it 
is primarily detected in the thickened granular and 
spinous layers of the epidermis.25 With regard to fi-
bronectin, both keloids and HS have more fibronec-
tin than normal skin. In HSs, it is diffusely located in 
a linear or curling arrangement throughout the der-
mis,26 whereas in keloids it is found intensely positive 
in the intercellular matrix.27
Roles of Dermal Fibroblasts
The excessive ECM in HSs and keloids is caused 
by the accumulation of dermal fibroblasts. This is the 
result of imbalances between fibroblast proliferation 
and apoptosis and between the subsequent protein 
products of fibroblasts. With regard to fibroblast pro-
liferation, while fibroblasts are the main cellular in-
gredients in normal dermal scars, they occur at higher 
densities in HSs and keloids. Keloids differ from HSs 
in having a higher proliferating cell nuclear antigen 
expression, which indicates that the fibroblasts in ke-
loids are more proliferative.28 With regard to fibroblast 
apoptosis, keloid-derived fibroblasts are significantly 
resistant to Fas-mediated apoptosis, in contrast to HS-
derived fibroblasts.29 This is supported by the fact that 
HSs can be induced in mice by applying mechanical 
stress early during the proliferative phase of wound 
healing: this upregulates the expression of the prosur-
vival marker Akt and inhibits cellular apoptosis.30 De-
layed fibroblast apoptosis may be responsible for the 
characteristic paucity of fibroblasts in the center of 
keloids: it is possible that this delay allows the cells to 
produce vast amounts of ECM before they eventually 
disappear, leaving only an acellular collagenous mass.
Roles of Dermal Mast Cells
Many studies have examined how the numbers 
and activities of mast cells (MCs) change in patholog-
ical scarring and how they interact with fibroblasts. In 
keloids, MCs are activated, as indicated by the upreg-
ulated expression of their specific activation marker 
MC β-tryptase.31 In HSs, the number of MCs is not 
increased compared to the number in normal scars.11
MC activation leads to the release via degranula-
tion of biological mediators that are known to pro-
mote fibrogenesis in scars. These mediators include 
histamine, which can stimulate the collagen synthe-
sis of keloid fibroblasts32,33; tryptase, which can pro-
mote the procollagen mRNA synthesis of normal 
dermal fibroblasts and stimulate their chemotaxis34; 
and chymase, which can cleave procollagen type I 
and thereby facilitate collagen fibril formation.35 A 
number of interactions between MCs and fibroblasts 
may also participate in the induction of fibrosis.   
For example, fibroblast-derived stem cell factor upreg-
ulates the expression and synthesis in MCs of monocyte 
chemoattractant protein-1, which in turn enhances 
collagen α1(I) mRNA expression in fibroblasts.36 In 
addition, MCs may activate fibroblasts through gap 
junction intercellular communication, thereby pro-
moting profibrotic fibroblast activities.37 Such hetero-
cellular gap junction intercellular communication 
between MCs and fibroblasts may also upregulate α-
SMA and thereby induce the transformation of fibro-
blasts into myofibroblasts. Indeed, knockdown in MCs 
of connexin-43 (the gap junction channel structural 
protein) retards that transformation.38 Notably, in pigs 
that produce some features of human HSs after they 
are wounded, the MC stabilizer ketotifen reduces scar 
formation and wound contraction: the ketotifen-treat-
ed pigs exhibit thinner and less dense collagen fibers 
and lower numbers of α-SMA+ myofibroblasts than the 
untreated pigs.39
HYPOTHESES ON THE ETIOLOGY OF 
PATHOLOGICAL SCARRING
Many studies have sought to describe and explain 
the pathogenesis of pathological scars, mainly from 
the perspectives of genetics, mechanics, endocrinol-
ogy, metabolism, circulation, immunology, and nu-
trition.
Keloid Genetics
The involvement of familial inheritance is indi-
cated by clinical evidence showing that patients with 
darker skin are 15 times more likely to develop patho-
logical scars, primarily keloids, and that these scars are 
absent in albinos.6 To date, potential keloid-associated 
loci in Japanese, African-American, and Han Chinese 
families have been identified on chromosomes 2q23, 
7p11,40 and 10q23.31,41 respectively, although the re-
sponsible genes have not yet been identified. More-
over, genome-wide association studies have shown 
that in the Japanese   population, 4 SNP (single nu-
cleotide polymorphism) loci (rs873549, rs1511412, 
rs940187, and rs8032158) in 3 chromosomal regions 
(1q41, 3q22.3–23, and 15q21.3) exhibit significant   Huang et al. • Keloid and Hypertrophic Scar Pathology
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  associations with keloids. Of these, rs873549 demon-
strated the most significant association.42
Mechanics Theory
The skin injury-wound tension theory is a mile-
stone in our understanding of keloid formation. Ke-
loids are frequently seen on the anterior chest and 
scapular regions but rarely on the scalp and anterior 
lower legs; this pattern correlates closely with the fre-
quencies with which these body regions are subjected 
to local physical tension or movement.43,44 Such site 
specificity can change when circumstances alter the 
local mechanics. For example, Africans and African-
Americans often develop scalp keloids because their 
tightly braided hair styles result in increased skin ten-
sion.45 In addition, the characteristic shapes of keloid 
scars, namely, the butterfly, crab’s claw, and dumbbell 
shapes, are largely determined by the direction of the 
local mechanical forces on the skin.46 Our previous 
review has described the potential molecular signal-
ing pathways behind this phenomenon.47
Endocrinological Hypothesis
Endocrinology-based theories suggest that patho-
logical scarring may be caused by physiological hy-
peractivity of the sebaceous gland. The sebum or 
sebocyte hypothesis is particularly attractive as it ex-
plains the distribution and behavior of keloids. Ke-
loids are rare in parts of the body that lack sebaceous 
glands, such as the palms and soles; they are also rare 
in animals that lack sebaceous glands. Moreover, se-
bum production is highly active in adolescence and 
early adulthood, which are periods that are associ-
ated with high incidences of keloids.48
Metabolic, Circulatory, Immunological,  
and Nutritional Points of View
Several theories revolving around metabolic, cir-
culatory, immunological, and nutritional issues have 
been proposed. Abnormal metabolic products have 
been detected in HSs and keloids. Keloids and HSs 
have higher adenosine triphosphate (ATP) levels; 
moreover, ATP levels in keloids are still high 10 years 
after the injury, although as time passes after the 
trauma these ATP levels drop.49 The possibility that 
abnormal scarring is associated with increased meta-
bolic activity is supported by the high oxygen con-
sumption rate and insufficient oxygen diffusion in 
HSs and keloids.50 However, it is unclear how these 
metabolic changes, including hypoxia in the central 
part of keloids, contribute to the formation of patho-
logical scars and whether they are causes or results.
With regard to circulation dynamics, many cases 
of severe keloid are associated with high blood pres-
sure (hypertension).51,52 An analysis of 100 consecu-
tive patients with keloid in our department revealed 
that patients with large keloids (more than 10 cm2) 
were significantly more likely to have hypertension 
than patients with mild keloids (less than 10 cm2).51 
This study suggests that either hypertension ad-
versely affects keloid tissues at a physiological level 
(eg, by elevating tissue pressure, capillary growth, or 
endothelial damage) or keloids and hypertension 
share an etiological mechanism.
Immunological mechanisms may also contribute 
to scar pathogenesis: the eluates of keloids but not 
HSs contain antinuclear antibodies against fibro-
blasts.53 However, the precise role that these antinu-
clear antibodies play in scar pathogenesis is unclear. 
In the nutritional hypothesis, it is suggested that 
pathogenic scars are caused by inadequate fatty acid 
nutrition. This hypothesis is still being developed by 
assessing patients with keloids for associations be-
tween immune or inflammatory responses and nu-
trition with fatty acids.19
It should be noted that the cause–effect rela-
tionship between the various proposed causes in 
these hypotheses and pathological scar formation 
remains to be verified and further delineated by fu-
ture studies.
CURRENT CLINICAL THERAPIES FOR 
PATHOLOGICAL SCARRING
Several clinical approaches have proved to be ef-
fective for treating HSs and keloids and preventing 
their recurrence. The most popular methods are di-
rect surgical excision with postsurgical radiotherapy, 
cryotherapy, and laser therapy. These methods focus 
on directly removing the accumulated cells and ECM 
in the pathogenic scars. Other approaches are based 
on cytotoxic agents such as bleomycin-puncture54 or 
5-fluorouracil-tattoo.55 The aim of the latter meth-
ods is to reduce cellular division and scar bulk. Sev-
eral other effective methods have been devised on 
the basis of the etiological theories described above. 
These include methods that are directly based on 
the mechanics theory. These tension-reduction or 
shielding methods aim to prevent the development 
of scars and include the use of z-plasties, w-plasties, 
and small-wave incision design,56 local flaps to cover 
the wound, subcutaneous/fascial sutures,57 and sili-
con sheeting.58 Similarly, another approach, the ap-
plication of snake oil in traditional African medicine, 
is a nutrition-based therapy that seems to have some 
efficacy.59 Finally, other interventions relate to some 
extent to the immunomodulation theory described 
above: they include imiquimod 5% cream applica-
tion.60 However, the exact mechanisms involved re-
main to be clarified.PRS GO • 2013
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FUTURE PERSPECTIVES
Pathologists and surgeons share a number of 
questions and interests regarding pathological scars: 
(1) Can a deeper understanding of aberrant scar 
pathogenesis be obtained by comparing pathological 
scars to local tumors such as basal cell carcinomas? 
Keloids seem to share several features with tumors. 
These include their ability to “invade” into adjacent 
healthy tissue without spontaneous regression, their 
strong resistance to apoptosis, and their tendency to 
recur after surgical excision. In addition, like basal 
cell carcinoma, keloids are aggressive locally: they 
generally do not have the malignant potential for 
metastasis. It would be of interest to identify the key 
factors that keep keloids and basal cell carcinoma 
confined vertically in the dermis. (2) Could compar-
ative studies with stem cells shed light on the patho-
genic mechanisms behind keloids/HSs? A recent 
study showed that keloid-derived mesenchymal-like 
stem cells isolated from keloid scalp tissues could dif-
ferentiate into adipocytes, osteoblasts, chondrocytes, 
smooth muscle cells, and angiogenic endothelial 
cells.61 It has also been proposed that mesenchymal 
stem cells may participate in keloid pathogenesis by 
differentiating toward keloid formation and pro-
gression.62 Thus, could the initiation of pathological 
scars relate to stem cell-like functions of keloid cells?
In summary, HSs and keloids are the result of 
aberrant wound healing. The pathogenesis of these 
pathological scars involves cellular and ECM compo-
nents in both the epidermal and dermal layers that 
are regulated by a wide array of interfering factors 
in the inflammation, proliferation, and remodeling 
phases. Concerted efforts by pathologists and plastic 
surgeons are needed to fuel the research that will 
unravel the mechanisms that underlie the forma-
tion of HS and keloids. This research is likely to be 
extremely beneficial in terms of identifying further 
preventative and therapeutic methods. 
Rei Ogawa, MD, PhD, FACS
Department of Plastic
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